The Experimental Drug Development Centre (EDDC), Singapore's national platform for drug discovery and development, is pleased to announce that the Phase 1 trial for EBC-129 has progressed into dose expansion.
May 24 2024Agency for Science, Technology and Research , Singapore The Experimental Drug Development Centre , Singapore's national platform for drug discovery and development, is pleased to announce that the Phase 1 trial for EBC-129 has progressed into dose expansion.
The Phase 1 trial began with a dose escalation study which evaluated the safety and tolerability of EBC-129 in patients with unresectable metastatic solid tumors. The first patient for the dose escalation was dosed at the National Cancer Centre Singapore in May 2023. EBC-129 is also being tested at the National University Cancer Institute, Singapore , as well as the MD Anderson Cancer Center and the University of Colorado Cancer Center in the United States.
The ADC and the immunohistochemistry -based test used for patient selection were developed collaboratively by NCCS, A*STAR's Bioprocessing Technology Institute and the Institute for Molecular and Cell Biology , as well as EDDC. Matthew Ng, Clinical Assistant Professor, Head, Department of Gastrointestinal and Neurological Medical Oncology, NCCS
Antigen Bioprocessing Cancer Cell Cholangiocarcinoma Clinical Trial Drug Discovery Healthcare Hospital Molecular Biology Oncology Pancreatic Cancer Proton Therapy Research Technology Therapeutics
South Africa Latest News, South Africa Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Watch: World Snooker Championship final - Wilson opens with 129 clearance against JonesWatch live BBC coverage of the World Snooker Championship 2024 at the Crucible Theatre in Sheffield.
Read more »
Watch: World Snooker Championship final - Wilson opens with 129 clearance against JonesWatch live BBC coverage of the World Snooker Championship 2024 at the Crucible Theatre in Sheffield.
Read more »
Dupilumab shows promising results in Phase 3 trial for COPD with type 2 inflammationChronic obstructive pulmonary disease patients with type 2 inflammation may soon gain access to a new drug -; dupilumab -; that showed rapid and sustained improvements in patients in a pivotal Phase 3 clinical trial, researchers report in the New England Journal of Medicine.
Read more »
Stoneman ton helps Middlesex to 303-6 against GlamorganMark Stoneman's 129 lead the way as Middlesex reached 303-6, 120 runs ahead of Glamorgan.
Read more »
What happens next as Yousaf faces no-confidence vote at Holyrood?If everyone takes part in the vote Mr Yousaf would need at least 64 of the 129 MSPs to vote for him.
Read more »
The tech wars are about to enter a fiery new phaseAmerica, China and the battle for supremacy
Read more »